Candel therapeutics announces pricing of public offering

Needham, mass., dec. 12, 2024 (globe newswire) -- candel therapeutics, inc. (“candel”) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. the gross proceeds from the offering to candel are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses. the offering is expected to close on or about december 16, 2024, subject to customary closing conditions. in addition, candel has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.
CADL Ratings Summary
CADL Quant Ranking